Pharsight

Chimerix patents expiration

1. Tembexa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9303051 CHIMERIX Phosphonate ester derivatives and methods of synthesis thereof
Aug, 2031

(7 years from now)

US8962829 CHIMERIX Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof
Oct, 2034

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10112909 CHIMERIX Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof
Oct, 2034

(11 years from now)

US10487061 CHIMERIX Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof
Oct, 2034

(11 years from now)

US9371344 CHIMERIX Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof
Oct, 2034

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Jun 4, 2024
Orphan Drug Exclusivity (ODE) Jun 4, 2028

Drugs and Companies using BRINCIDOFOVIR ingredient

Market Authorisation Date: 04 June, 2021

Treatment: Method of treating human smallpox disease

Dosage: SUSPENSION;ORAL

More Information on Dosage

TEMBEXA family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic